AI Stock Analysis - Lenz Therapeutics (LENZ)
Analysis generated October 2, 2025.
Lenz Therapeutics is a biopharmaceutical company primarily focused on the development and commercialization of innovative therapies for eye diseases. The company has a strong pipeline of drugs targeting unmet medical needs in ophthalmology, including treatments for dry eye disease and age-related macular degeneration. Operating in a highly specialized sector, Lenz Therapeutics positions itself as a leader in pioneering treatments to improve the quality of life for patients suffering from severe eye conditions.
Stock Alerts - Lenz Therapeutics (LENZ)
 |
Lenz Therapeutics | May 12 Price is down by -28.9% in the last 24h. |
|
Lenz Therapeutics | May 6 Price is up by 6.2% in the last 24h. |
|
Lenz Therapeutics | April 23 Price is down by -6.4% in the last 24h. |
|
Lenz Therapeutics | April 13 Price is up by 6.1% in the last 24h. |
Download our app on iOS or Android to get future alerts delivered in real-time.
Alternative Data for Lenz Therapeutics
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 22 | Sign up | Sign up | Sign up |
| Sentiment | 62 | Sign up | Sign up | Sign up |
| Webpage traffic | 7,000 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Subscribers | 90 | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 19 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 1,275 | Sign up | Sign up | Sign up |
| X Followers | 111 | Sign up | Sign up | Sign up |
| X Mentions | 19 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Linkedin Employees | 177 | Sign up | Sign up | Sign up |
About Lenz Therapeutics
LENZ Therapeutics, Inc. operates as a biopharmaceutical company that focuses on the development and commercialization of therapies to improve vision in the United States.
| Price | $8.05 |
| Target Price | Sign up |
| Volume | 640,400 |
| Market Cap | $248M |
| Year Range | $7.91 - $49.05 |
| Dividend Yield | 0% |
| Analyst Rating | 100% buy |
| Industry | Biotechnology |
In the news
LENZ Therapeutics Q4 Earnings Call HighlightsMarch 24 - Yahoo Entertainment |
|
Why Lenz Therapeutics Stock Crashed TodayMarch 24 - Yahoo Entertainment |
|
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZJanuary 20 - GlobeNewswire |
|
 |
Lenz Therapeutics, Sarah Jessica Parker launch 'Make it VIZZable'January 14 - Thefly.com |
Presbyopia Market to Witness Accelerated Growth at a CAGR of 4.9% During the Forecast Period (2026–2036) Supported by Expanding Treatment Landscape | DelveInsightMay 11 - GlobeNewswire |
|
Pharmaceutical and Biotechnology Royalty Rates Agreements Report and Directory 2026: Insights Into 1,567 Licensing Transactions by Company A-Z, Therapeutic Area, Technology, Headline ValueMarch 12 - GlobeNewswire |
|
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '25 | 13M | 130,000 | 12M | -17M | -17M | -0.590 |
| Q2 '25 | 5M | 19,000 | 5M | -15M | -17M | -0.530 |
| Q1 '25 | 0 | 36,000 | -36,000 | -15M | -17M | -0.530 |
| Q4 '24 | 66,000 | 33,000 | 33,000 | -13M | -15M | -0.460 |
| Q3 '24 | 0 | 10,000 | -10,000 | -10M | -13M | -0.380 |
Insider Transactions View All
| Chevallard Daniel R. filed to buy 12,886 shares at $8.6. March 30 '26 |
| George Jeffrey P. filed to buy 5,592 shares at $8.9. March 30 '26 |
| Schimmelpennink Evert B. filed to buy 77,289 shares at $9. March 30 '26 |
| Olsson Shawn filed to sell 10,521 shares at $25.7. November 19 '25 |
| Olsson Shawn filed to sell 4,733 shares at $26.4. November 19 '25 |
Similar companies
Read more about Lenz Therapeutics (LENZ) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, 4chan mentions, reddit mentions, reddit subscribers, stocktwits mentions, stocktwits subscribers, x followers, x mentions, news mentions, customer reviews & linkedin employees.
FAQ - Lenz Therapeutics
The Market Cap of Lenz Therapeutics is $248M.
Currently, the price of one share of Lenz Therapeutics stock is $8.05.
The LENZ stock price chart above provides a comprehensive visual representation of Lenz Therapeutics' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Lenz Therapeutics shares. Our platform offers an up-to-date LENZ stock price chart, along with technical data analysis and alternative data insights.
As of our latest update, Lenz Therapeutics (LENZ) does not offer dividends to its shareholders. Investors interested in Lenz Therapeutics should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
Some of the similar stocks of Lenz Therapeutics are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
